JAC Advance Access published online on February 11, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg127
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Department of Infectious
Diseases, Auckland Hospital, Private Bag 92024, Auckland
* Corresponding author. E-mail: ArloU{at}adhb.govt.nz.
Received 21 October 2002
; revised 21 November 2002
; accepted 17 December 2002
Objectives: To describe trends in
mupirocin resistance among Staphylococcus aureus in
New Zealand (NZ), following the availability of mupirocin in 1986. Patients and methods: Data from a variety of
sources were used for this study: susceptibility data collected
annually from diagnostic laboratories throughout NZ; a local survey
of mupirocin-resistant S. aureus in the Auckland
area in 1997; a national survey of S. aureus antimicrobial susceptibility
in 1999; and the national methicillin-resistant S. aureus (MRSA)
surveillance programme. Results: All data sources show that there was
a steady increase in mupirocin resistance among S. aureus throughout
the 1990s, and rates in NZ are now markedly higher than those reported
in most other comparable countries. By 1999, resistance averaged
28%, with higher rates among community-acquired compared
with hospital-acquired isolates, and with a wide geographical variation
in resistance. Resistance was more common among S. aureus generally
than MRSA. Conclusion: We postulate that the steady rise
in mupirocin resistance among S. aureus in
NZ throughout the 1990s may be due, at least in part,
to the over the counter availability of mupirocin from 1991 to 2000.
The current patterns of mupirocin consumption need to be reviewed
and its use rationalized to maximize the chances of this antibiotic
retaining beneficial antistaphylococcal activity.
Keywords: mupirocin, Staphylococcus aureus,
resistance
Mupirocin and Staphylococcus aureus:
a recent paradigm of emerging antibiotic resistance
2 Department of Microbiology, Middlemore
Hospital, Auckland
3 Antibiotic
Reference Laboratory,
Institute of Environmental Science and Research, Wellington, New
Zealand
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Babu, V. Rekasius, J. P. Parada, P. Schreckenberger, and M. Challapalli Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus-Colonized Patients at Admission to a Tertiary Care Medical Center J. Clin. Microbiol., July 1, 2009; 47(7): 2279 - 2280. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Malaviolle, C. Nonhoff, O. Denis, S. Rottiers, and M. J. Struelens Evaluation of disc diffusion methods and Vitek 2 automated system for testing susceptibility to mupirocin in Staphylococcus aureus J. Antimicrob. Chemother., November 1, 2008; 62(5): 1018 - 1023. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Simor, T. L. Stuart, L. Louie, C. Watt, M. Ofner-Agostini, D. Gravel, M. Mulvey, M. Loeb, A. McGeer, E. Bryce, et al. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3880 - 3886. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Perez-Roth, C. Lopez-Aguilar, J. Alcoba-Florez, and S. Mendez-Alvarez High-Level Mupirocin Resistance within Methicillin-Resistant Staphylococcus aureus Pandemic Lineages. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3207 - 3211. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Schaffer, R. M. Solinga, J. Cocchiaro, M. Portoles, K. B. Kiser, A. Risley, S. M. Randall, V. Valtulina, P. Speziale, E. Walsh, et al. Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model Infect. Immun., April 1, 2006; 74(4): 2145 - 2153. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Rouse, M. Rotger, K. E. Piper, J. M. Steckelberg, M. Scholz, J. Andrews, and R. Patel In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3187 - 3191. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Walker, F. Levy, M. Shorman, G. David, J. Abdalla, and F. A. Sarubbi A Decline in Mupirocin Resistance in Methicillin-Resistant Staphylococcus aureus Accompanied Administrative Control of Prescriptions J. Clin. Microbiol., June 1, 2004; 42(6): 2792 - 2795. [Abstract] [Full Text] [PDF] |
||||



